DUBLIN, March 3, 2016 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/8s8p7d/global_dendritic) has announced the addition of the "Global Dendritic Cell Cancer Vaccine Market Outlook 2020" report to their offering.
There are several combinational therapies wherein dendritic cells are administered along with monoclonal antibodies, antibody-drug conjugates and peptide based vaccines to increase the efficacy of the vaccines. This is because of the fact that in the cancer patients, the immune system is already compromised, besides the tumor microenvironment which negates the mechanism of action of immunological cells. The role of conventional therapy like chemotherapy, surgical removal of tumor cells or radiotherapy also needs to be underscored as they help in reducing the bulk of tumorous growth. The cancer based vaccines when administered thereafter, is reported to have increased efficiency.
As dendritic cells are found to have a modulatory effect on almost all the parameters of the immune system, all other types of cancer vaccines are found to be administered in conjugation with dendritic cells cancer vaccine to have a synergistic effect on immune system against tumor growth. With further advancement in immunological studies, dendritic cells cancer vaccine will have a driving effect on cancer therapeutics which will have a lion's share on cancer vaccine market.
Key Topics Covered:
Companies Mentioned:
Report Structure:
1. Dendritic Cells Cancer Vaccine: The Genesis
2. Classification of Dendritic Cells
3. Mechanism of Action of Dendritic Cells
4. New Vaccine Strategies That Exploit Dendritic Cells Biochemistry
5. Dendritic Cell Cancer Vaccine Market & Clinical Insight
6. A Comparative Insight of Dendritic Cell Vaccines & its Peers
7. The Growth Factors: Why the Fixation with Dendritic Cell Cancer Vaccines?
8. Road Ahead: Dendritic Cell Cancer Vaccine in the Challenging Horizon of Cancer Immunotherapy
9. Conclusion: Dendritic Cell Cancer Vaccine; a Silver Lining to the Dark Under-Belly of Cancer
10. Dendritic Cell Cancer Vaccine Clinical Pipeline By Country, Company, Indication & Phase
11. Marketed Dendritic Cell Cancer Vaccine: CreaVax® ( Renal Cancer, South Korea)
12. Market Withdrawl: Provenge by Dendreon Corporation
13. Discontinued & Suspended Dendritic Cell Cancer Vaccine in Clinical Trials
14. Competitve Landscape
For more information visit http://www.researchandmarkets.com/research/8s8p7d/global_dendritic
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article